GENE ONLINE|News &
Opinion
Blog

2021-05-29| Asia-PacificR&D

HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs

by Kathy Huang
Share To

Jin Li, Chairman & CEO of HitGen Image source: www.163.com

China-based pharmaceutical company HitGen has announced a research collaboration with Dorian Therapeutics on May 24th. Under the agreement, HitGen will receive an undisclosed upfront payment from Dorian.

HitGen, renowned for its DNA-encoded libraries (DEL) in early drug discovery and is profited by it. DEL enables the synthesis and screening of unprecedented chemicals more efficiently, and it is now available for over 1 trillion DNA-encoded compounds. The collaboration with Dorian shows HitGen’s ambition to expand its pharmaceutical business in age-related diseases.

 

Senoblockers – Treatments Enhancing Regenerative Capacity of Aging cells

Senoblockers are treatments for aging diseases developed by Dorian. They act on aged tissues to reactivate the generation of cells, which provide therapeutics for aging diseases like Alzheimer’s, osteoporosis, and autoimmune diseases. HitGen will apply its platform technology to those disease targets senoblockers treat for.

 

Previous Collaborations

On April 6th, HitGen signed a drug discovery collaboration with BioAge, a company specializing in building biobanks that identify drug targets of elderly diseases. The partnership with BioAge and Dorian has the potential for HitGen to open up markets on age-associated diseases.

“We look forward to working with Dorian to identify novel small molecule starting points from DNA-encoded libraries,” Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, “We will work closely with Dorian scientists to generate new lead compounds for their research programs to address unmet medical needs associated with aging.”

Related Article: AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Lower Waist-to-Hip Ratio in Midlife Associated with Better Cognitive Function in Later Years
2025-03-14
Study Reveals Antidepressants May Hasten Cognitive Decline in Dementia Patients
2025-03-03
First-of-its-kind AI Model Uses Brain Scans to Reveal Link Between Aging and Cognitive Decline
2025-02-25
LATEST
Comparative Analysis of Tirzepatide (Zepbound/Mounjaro) and Semaglutide (Wegovy) for Weight Loss
2025-05-12
Donald Trump’s “Most Favored Nation” Executive Order on Drug Pricing
2025-05-12
Discover Investment Opportunities & Innovation at International Healthcare Week in Hong Kong from May
2025-05-12
The Buffett Paradox: Cola, Happiness, and a Biotech Longevity Enigma
2025-05-11
President to Sign Executive Order on Trade Enforcement Monday Morning
2025-05-11
Trump to Sign Executive Order Linking U.S. Drug Prices to International Levels.
2025-05-11
Podcast Highlights Agile Biopharmaceutical Firms’ Strategies for Navigating Complex Clinical Trials
2025-05-11
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top